Product Pipeline

Product Pipeline Development

PRODUCT I
Inimex will initially develop the first IDR product, IMX942, for hospital bacterial infections - which represent high medical need due to the seriousness of disease in the hospital setting, the high cost of treatment, and the high incidence of antibiotic resistance. Major indications that Inimex will evaluate in the arena include hospital-treated pneumonia, surgical site infections, and chemotherapy-induced neutropenia.

PRODUCT II
The second Inimex IDR product development program will target inflammation, a distinct disease pathophysiology from the lead program. Inimex is currently evaluating compounds in relevant chronic inflammation models to define a clincal development program for inflammatory disease. Candidate indications from include moderate to severe rheumatoid arthritis and psoriasis.

For more information

> Inimex Product Profile
   193KB pdf format